Results 41 to 50 of about 9,967 (136)
Hematological OncologyAbstract Chronic lymphocytic leukemia (CLL) is the most common leukemia in western societies, recognized by clinical and molecular heterogeneity. Despite the success of targeted therapies, acquired resistance remains a challenge for relapsed and refractory CLL, as a consequence of mutations in the target or the upregulation of other ...
Mouawad, Nayla +6 more
openaire +2 more sources
Cancer Medicine, Volume 15, Issue 6, June 2026.ABSTRACT The gut microbiome has emerged as a pivotal regulator of immunotherapy efficacy in non‐small cell lung cancer (NSCLC), with mounting evidence demonstrating that microbial‐immune crosstalk significantly influences therapeutic responses. Current research reveals that commensal bacteria modulate host immunity through complex metabolic and ...
Liming Zhu +4 more
wiley +1 more source
The Wnt5a Receptor, Receptor Tyrosine Kinase-Like Orphan Receptor 2, Is a Predictive Cell Surface Marker of Human Mesenchymal Stem Cells with an Enhanced Capacity for Chondrogenic Differentiation [PDF]
Stem Cells, 2017 Abstract Multipotent mesenchymal stem cells (MSCs) have enormous potential in tissue engineering and regenerative medicine. However, until now, their development for clinical use has been severely limited as they are a mixed population of cells with varying capacities for lineage differentiation and tissue formation. Here, we identify
Sally C. Dickinson +15 more
openaire +5 more sources
Cancer Reports, Volume 9, Issue 6, June 2026.ABSTRACT Background This retrospective series reports outcomes and prognostic factors for advanced chordoma (AC) treatment with molecular targeted therapies (MTTs) in different treatment lines. Methods This is a retrospective series of 57 patients with AC treated between 2004 and 2023 at one of seven participating sarcoma centres.
Astrid Lipplaa +10 more
wiley +1 more source
Biomedicine & Pharmacotherapy, 2017 Chronic lymphocytic leukemia (CLL) is characterized by reposition of malignant B cells in the blood, bone marrow, spleen and lymph nodes. It remains the most common leukemia in the Western world. Within the recent years, major breakthroughs have been made to prolong the survival and improve the health of patients.
Leili, Aghebati-Maleki +5 more
openaire +2 more sources
Wnt5a induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell carcinoma cells
Cancer Management and Research, 2019 Xuping Wu,1 Ting Yan,2 Leiyu Hao,3 Yichao Zhu3,41The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing 210003, People’s Republic of China; 2Safety Assessment and Research Center for Drug, Pesticide and Veterinary Drug of ...
Wu X, Yan T, Hao L, Zhu Y
doaj
iLABMED, Volume 4, Issue 2, Page 91-107, June 2026.This article reviews the pivotal role of post‐translational modifications of proteins in the development and progression of hematologic malignancies, and explores their clinical translation potential as novel biomarkers and therapeutic targets. ABSTRACT Post‐translational modifications (PTMs) of proteins have emerged as critical regulators in the ...
Yuxuan Han +6 more
wiley +1 more source
Progress in Natural Products Target Discovery Technology
MedComm, Volume 7, Issue 6, June 2026.Here, we provide a comprehensive overview of current technologies and recent advancements in therapeutic target discovery for natural products. By systematically synthesizing the principles, methodologies, and practical applications of existing experimental and computational strategies, this work provides a more actionable reference framework for ...
Qiyuan Pan +7 more
wiley +1 more source
Blood, 2018 Abstract ROR1 is an onco-embryonic surface antigen expressed on chronic lymphocytic leukemia (CLL) and a variety of other cancers, but not on most normal adult tissues. We generated a humanized IgG1 monoclonal antibody (mAb) cirmtuzumab (formerly UC-961) that binds with high affinity to a specific extracellular epitope of human ROR1 and ...
Yousaf A. Mian +5 more
openaire +1 more source
, 2017 Ovarian cancer survival rates remain at 40% due to late stage disease at diagnosis. The current treatment regimens of cytoreductive surgery and carboplatin/paclitaxel chemo therapy have not changed in the past thirty years and women often experience cancer recurrence. Therefore, there is an important need for molecular biomarkers and targeted therapies
openaire +2 more sources